K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.23 CAD 0.77%
Market Cap: 527.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one GUD stock under the Base Case scenario is 4.95 CAD. Compared to the current market price of 5.23 CAD, Knight Therapeutics Inc is Overvalued by 5%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GUD Intrinsic Value
4.95 CAD
Overvaluation 5%
Intrinsic Value
Price
K
Worst Case
Base Case
Best Case

Valuation History
Knight Therapeutics Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
GUD
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for GUD cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about GUD?
Bearish
Neutral
Bullish

Fundamental Analysis

5.23 CAD
+0.77%
+0.77%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Knight Therapeutics Inc
CA
Pharmaceuticals
Market Cap
528.1m CAD
IPO
Feb 28, 2014
Employees
660
Canada
Market Cap
528.1m CAD
Industry
Pharmaceuticals
IPO
Feb 28, 2014
Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Knight Therapeutics Inc

Provide an overview of the primary business activities
of Knight Therapeutics Inc.

What unique competitive advantages
does Knight Therapeutics Inc hold over its rivals?

What risks and challenges
does Knight Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Knight Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Knight Therapeutics Inc.

Provide P/S
for Knight Therapeutics Inc.

Provide P/E
for Knight Therapeutics Inc.

Provide P/OCF
for Knight Therapeutics Inc.

Provide P/FCFE
for Knight Therapeutics Inc.

Provide P/B
for Knight Therapeutics Inc.

Provide EV/S
for Knight Therapeutics Inc.

Provide EV/GP
for Knight Therapeutics Inc.

Provide EV/EBITDA
for Knight Therapeutics Inc.

Provide EV/EBIT
for Knight Therapeutics Inc.

Provide EV/OCF
for Knight Therapeutics Inc.

Provide EV/FCFF
for Knight Therapeutics Inc.

Provide EV/IC
for Knight Therapeutics Inc.

Show me price targets
for Knight Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Knight Therapeutics Inc?

How accurate were the past Revenue estimates
for Knight Therapeutics Inc?

What are the Net Income projections
for Knight Therapeutics Inc?

How accurate were the past Net Income estimates
for Knight Therapeutics Inc?

What are the EPS projections
for Knight Therapeutics Inc?

How accurate were the past EPS estimates
for Knight Therapeutics Inc?

What are the EBIT projections
for Knight Therapeutics Inc?

How accurate were the past EBIT estimates
for Knight Therapeutics Inc?

Compare the revenue forecasts
for Knight Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Knight Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Knight Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Knight Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Knight Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Knight Therapeutics Inc with its peers.

Analyze the financial leverage
of Knight Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Knight Therapeutics Inc.

Provide ROE
for Knight Therapeutics Inc.

Provide ROA
for Knight Therapeutics Inc.

Provide ROIC
for Knight Therapeutics Inc.

Provide ROCE
for Knight Therapeutics Inc.

Provide Gross Margin
for Knight Therapeutics Inc.

Provide Operating Margin
for Knight Therapeutics Inc.

Provide Net Margin
for Knight Therapeutics Inc.

Provide FCF Margin
for Knight Therapeutics Inc.

Show all solvency ratios
for Knight Therapeutics Inc.

Provide D/E Ratio
for Knight Therapeutics Inc.

Provide D/A Ratio
for Knight Therapeutics Inc.

Provide Interest Coverage Ratio
for Knight Therapeutics Inc.

Provide Altman Z-Score Ratio
for Knight Therapeutics Inc.

Provide Quick Ratio
for Knight Therapeutics Inc.

Provide Current Ratio
for Knight Therapeutics Inc.

Provide Cash Ratio
for Knight Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Knight Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Knight Therapeutics Inc?

What is the current Free Cash Flow
of Knight Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Knight Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Knight Therapeutics Inc

Current Assets 397.6m
Cash & Short-Term Investments 172.3m
Receivables 103m
Other Current Assets 122.2m
Non-Current Assets 564.7m
Long-Term Investments 105.6m
PP&E 21.6m
Intangibles 364.5m
Other Non-Current Assets 73m
Current Liabilities 118.2m
Accounts Payable 86.6m
Other Current Liabilities 31.5m
Non-Current Liabilities 70.2m
Long-Term Debt 36.5m
Other Non-Current Liabilities 33.7m
Efficiency

Earnings Waterfall
Knight Therapeutics Inc

Revenue
348.6m CAD
Cost of Revenue
-180.4m CAD
Gross Profit
168.3m CAD
Operating Expenses
-167m CAD
Operating Income
1.3m CAD
Other Expenses
-32m CAD
Net Income
-30.7m CAD

Free Cash Flow Analysis
Knight Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GUD Profitability Score
Profitability Due Diligence

Knight Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
ROIC is Increasing
38/100
Profitability
Score

Knight Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

GUD Solvency Score
Solvency Due Diligence

Knight Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Negative Net Debt
Low D/E
Short-Term Solvency
64/100
Solvency
Score

Knight Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GUD Price Targets Summary
Knight Therapeutics Inc

Wall Street analysts forecast GUD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GUD is 7.23 CAD with a low forecast of 6.16 CAD and a high forecast of 9.45 CAD.

Lowest
Price Target
6.16 CAD
18% Upside
Average
Price Target
7.23 CAD
38% Upside
Highest
Price Target
9.45 CAD
81% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GUD?

Click here to dive deeper.

Dividends

Knight Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GUD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one GUD stock?

The intrinsic value of one GUD stock under the Base Case scenario is 4.95 CAD.

Is GUD stock undervalued or overvalued?

Compared to the current market price of 5.23 CAD, Knight Therapeutics Inc is Overvalued by 5%.

Back to Top